These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 32702730)

  • 21. Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining.
    Liu TP; Hsieh YY; Chou CJ; Yang PM
    R Soc Open Sci; 2018 Nov; 5(11):181321. PubMed ID: 30564416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational-based drug repurposing methods in COVID-19.
    Masoudi-Sobhanzadeh Y
    Bioimpacts; 2020; 10(3):205-206. PubMed ID: 32793443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomics deliberations of 2-deoxy-d-glucose in the treatment of COVID-19 disease: an in silico approach.
    Prabhu NB; Vinay CM; Satyamoorthy K; Rai PS
    3 Biotech; 2022 Nov; 12(11):287. PubMed ID: 36164436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corrigendum to "In silico drug repurposing against SARS-CoV-2 using an integrative transcriptomic profiling approach: Hydrocortisone and Benzhydrocodone as potential drug candidates against COVID-19" [Infection, Genetics and Evolution 103 (2022) 105318].
    Mirmohammadi SM; Kianmehr A; Sabbaghian A; Mohebbi A; Shahbazmohammadi H; Sheikharabi M; Bazzi Z
    Infect Genet Evol; 2022 Oct; 104():105361. PubMed ID: 36089457
    [No Abstract]   [Full Text] [Related]  

  • 25. [Modulation of transcriptomic signature of the infected host: a new therapeutic strategy for the management of severe viral infections? Example of the flu].
    Poissy J; Terrier O; Lina B; Textoris J; Rosa-Calatrava M
    Reanimation; 2016; 25(Suppl 2):53-61. PubMed ID: 32288744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 Drug Repurposing: A Network-Based Framework for Exploring Biomedical Literature and Clinical Trials for Possible Treatments.
    Hamed AA; Fandy TE; Tkaczuk KL; Verspoor K; Lee BS
    Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CovMulNet19, Integrating Proteins, Diseases, Drugs, and Symptoms: A Network Medicine Approach to COVID-19.
    Verstraete N; Jurman G; Bertagnolli G; Ghavasieh A; Pancaldi V; De Domenico M
    Netw Syst Med; 2020; 3(1):130-141. PubMed ID: 33274348
    [No Abstract]   [Full Text] [Related]  

  • 28.
    López-Cortés A; Guevara-Ramírez P; Kyriakidis NC; Barba-Ostria C; León Cáceres Á; Guerrero S; Ortiz-Prado E; Munteanu CR; Tejera E; Cevallos-Robalino D; Gómez-Jaramillo AM; Simbaña-Rivera K; Granizo-Martínez A; Pérez-M G; Moreno S; García-Cárdenas JM; Zambrano AK; Pérez-Castillo Y; Cabrera-Andrade A; Puig San Andrés L; Proaño-Castro C; Bautista J; Quevedo A; Varela N; Quiñones LA; Paz-Y-Miño C
    Front Pharmacol; 2021; 12():598925. PubMed ID: 33716737
    [No Abstract]   [Full Text] [Related]  

  • 29. No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.
    Rogosnitzky M; Berkowitz E; Jadad AR
    JMIRx Med; 2020; 1(1):e19583. PubMed ID: 33724265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antidepressant drug treatment protecting from COVID-19: one more piece in the repurposing puzzle.
    Stingl JC
    BJPsych Open; 2021 Dec; 8(1):e20. PubMed ID: 34924095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of pharmacogenomic agreement.
    Safikhani Z; El-Hachem N; Quevedo R; Smirnov P; Goldenberg A; Juul Birkbak N; Mason C; Hatzis C; Shi L; Aerts HJ; Quackenbush J; Haibe-Kains B
    F1000Res; 2016; 5():825. PubMed ID: 27408686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.
    Barh D; Aljabali AA; Tambuwala MM; Tiwari S; Serrano-Aroca Á; Alzahrani KJ; Silva Andrade B; Azevedo V; Ganguly NK; Lundstrom K
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34067609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CPDR: An R Package of Recommending Personalized Drugs for Cancer Patients by Reversing the Individual's Disease-Related Signature.
    Chen R; Wang X; Deng X; Chen L; Liu Z; Li D
    Front Pharmacol; 2022; 13():904909. PubMed ID: 35795573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience.
    Gozzo L; Longo L; Vitale DC; Drago F
    Front Pharmacol; 2020; 11():588132. PubMed ID: 33101042
    [No Abstract]   [Full Text] [Related]  

  • 35. The (Still Unknown) Hypothetical Protective Role of COVID-19 Therapy in Bladder Cancer.
    Di Gianfrancesco L
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Computational Framework to Characterize the Cancer Drug Induced Effect on Aging Using Transcriptomic Data.
    Zhao Y; Wang Y; Yang D; Suh K; Zhang M
    Front Pharmacol; 2022; 13():906429. PubMed ID: 35847024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editorial: Drug Repurposing for COVID-19 Therapy.
    Maldonado R; Drago F
    Front Pharmacol; 2021; 12():748886. PubMed ID: 34504433
    [No Abstract]   [Full Text] [Related]  

  • 38. [Not Available].
    Ulas T; Aschenbrenner AC
    Biospektrum (Heidelb); 2021; 27(4):372-375. PubMed ID: 34219982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational drug repurposing in the age of COVID-19: mixing antiviral cocktails in silico.
    Diao JA; Raza MM; Venkatesh KP; Kvedar JC
    NPJ Digit Med; 2022 Apr; 5(1):52. PubMed ID: 35459899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repurposing Antimalarials to Tackle the COVID-19 Pandemic: (Trends in Parasitology 37, 8-11; 2021).
    Krishna S; Augustin Y; Wang J; Xu C; Staines HM; Platteeuw H; Kamarulzaman A; Sall A; Kremsner P
    Trends Parasitol; 2021 Apr; 37(4):357. PubMed ID: 33541791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.